Clinical manifestations of diffuse large B‑cell lymphoma
in the skin and subcutaneous tissue a case series study

Dulik, Katarzyna; Kamińska‐Winciorek, Grażyna; Swoboda, Ryszard; Kwiatkowska-Pamuła, Anna; Giebel, Sebastian

doi:10.5114/ada.2020.100494

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possible differential diagnoses include epidermoid cysts, angiolipomas and angiomyolipomas. The identification of cutaneous disease has prognostic importance since secondary cutaneous diffuse large B‐cell lymphoma has a higher international prognostic index score 5,6 . As such, a high index of suspicion is required when evaluating new “lipoma‐like” lesions in the context of a patient with DLBCL.…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous nodules in a patient with diffuse large B‐cell lymphoma

Lui,

Koh,

Chandran

2023

JEADV Clinical Practice

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Subcutaneous nodules in a patient with diffuse large B‐cell lymphoma

Lui,

Koh,

Chandran

2023

JEADV Clinical Practice

View full text Add to dashboard Cite

Antineoplastics

2021

Reactions Weekly

View full text Add to dashboard Cite

Disulfidptosis: A Novel Prognostic Criterion and Potential Treatment Strategy for Diffuse Large B-Cell Lymphoma (DLBCL)

Wang,

Tsukamoto,

Hori

et al. 2024

IJMS

View full text Add to dashboard Cite

Diffuse Large B-cell Lymphoma (DLBCL), with its intrinsic genetic and epigenetic heterogeneity, exhibits significantly variable clinical outcomes among patients treated with the current standard regimen. Disulfidptosis, a novel form of regulatory cell death triggered by disulfide stress, is characterized by the collapse of cytoskeleton proteins and F-actin due to intracellular accumulation of disulfides. We investigated the expression variations of disulfidptosis-related genes (DRGs) in DLBCL using two publicly available gene expression datasets. The initial analysis of DRGs in DLBCL (GSE12453) revealed differences in gene expression patterns between various normal B cells and DLBCL. Subsequent analysis (GSE31312) identified DRGs strongly associated with prognostic outcomes, revealing eight characteristic DRGs (CAPZB, DSTN, GYS1, IQGAP1, MYH9, NDUFA11, NDUFS1, OXSM). Based on these DRGs, DLBCL patients were stratified into three groups, indicating that (1) DRGs can predict prognosis, and (2) DRGs can help identify novel therapeutic candidates. This study underscores the significant role of DRGs in various biological processes within DLBCL. Assessing the risk scores of individual DRGs allows for more precise stratification of prognosis and treatment strategies for DLBCL patients, thereby enhancing the effectiveness of clinical practice.

show abstract

Clinical manifestations of diffuse large B‑cell lymphoma in the skin and subcutaneous tissue a case series study

Cited by 3 publications

References 14 publications

Subcutaneous nodules in a patient with diffuse large B‐cell lymphoma

Subcutaneous nodules in a patient with diffuse large B‐cell lymphoma

Antineoplastics

Disulfidptosis: A Novel Prognostic Criterion and Potential Treatment Strategy for Diffuse Large B-Cell Lymphoma (DLBCL)

Contact Info

Product

Resources

About